AbolerIS Pharma
PrivateLast Round
Series A
Sep 18, 2023
Total Funding Raised
$32.01M
Company Overview
AbolerIS Pharma is a biotechnology company that develops novel therapeutic approaches to induce immune tolerance for treating inflammatory, autoimmune, and degenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AbolerIS Pharma Comps
Public and private peers based on sector, stage, and business model.
AbolerIS Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 18, 2023 | ||||
| Seed | Nov 4, 2020 |
AbolerIS Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Caixa Capital Risc | Series A |
| Sambrinvest | Series A |
| Sound Bioventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 30, 2025
Philippe Alen appointed as the new Chief Business Officer.
AbolerIS Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AbolerIS Pharma's valuation, stock price, and market status.
